Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.72 NOK | -1.04% | +4.00% | +17.70% |
Sales 2023 | - | Sales 2024 * | 6.3M 572K | Capitalization | 229M 20.8M |
---|---|---|---|---|---|
Net income 2023 | -87 -7.89 | Net income 2024 * | - | EV / Sales 2023 * | - |
Net cash position 2023 * | 49.6M 4.5M | Net cash position 2024 * | 61.8M 5.61M | EV / Sales 2024 * | 26.6 x |
P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 8 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 53.93% |
Latest transcript on Lytix Biopharma
1 day | -1.04% | ||
1 week | +4.00% | ||
Current month | -6.23% | ||
1 month | -12.00% | ||
3 months | -21.64% | ||
6 months | -14.63% | ||
Current year | +17.70% |
Managers | Title | Age | Since |
---|---|---|---|
Øystein Rekdal
CEO | Chief Executive Officer | - | 02-12-31 |
Gjest Breistein
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | 07-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kjetil Hestdal
BRD | Director/Board Member | 64 | 21-06-06 |
Director/Board Member | 66 | 21-06-06 | |
Jayson M. Rieger
BRD | Director/Board Member | 48 | 21-06-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 5.72 | -1.04% | 113 426 |
24-04-25 | 5.78 | +7.04% | 204,090 |
24-04-24 | 5.4 | +0.75% | 14,221 |
24-04-23 | 5.36 | -3.60% | 85,174 |
24-04-22 | 5.56 | +4.91% | 12,663 |
Real-time Oslo Bors, April 26, 2024 at 10:45 am EDT
More quotesChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+17.70% | 21.08M | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- LYTIX Stock